Meet internationally-recognised haematologists Prof. Mathias Rummel and Prof. Martin Dreyling, both of whom specialise in the treatment and management of lymphomas.
Prof. Rummel talks about the pivotal StiL trial and shares long-term results from its 10-year analysis, highlighting the benefits of an extended time to next treatment with RIBOMUSTIN.
Prof. Dreyling talks about the 5-year results from the BRIGHT trial, highlighting data on survival and response rates with RIBOMUSTIN + rituximab versus R-CHOP/R-CVP.
Prof. Dreyling addresses differences between the two trials assessing RIBOMUSTIN and shares his expert nsights on treatment choices in follicular lymphoma.
RIBOMUSTIN® is a registered trademark of Janssen-Cilag Pty Ltd, ABN 47 000 129 975, 1–5 Khartoum Road, Macquarie Park NSW 2113. Ph: 1800 226 334. Date of preparation: September 2017. CP-01826. JRI0026.